ARTICLE | Clinical News

FDA approves sNDA for Sunovion's Aptiom

October 20, 2017 12:28 AM UTC

FDA approved an sNDA for Aptiom eslicarbazepine acetate (BIA 2-093, SEP-0002093) from the Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) to treat partial-onset seizures in patients age ≥4. Aptiom is already approved for the indication in adults...